Jazz Pharmaceuticals has filed a patent for the use of cannabidiol (CBD) in treating seizures associated with rare epilepsy syndromes caused by brain injury, specifically in patients diagnosed with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. The patent claims a CBD preparation with over 95% CBD and between 0.01 and 0.15% tetrahydrocannabinol (THC) for this purpose. The preferred dosage of CBD is between 5 mg/kg/day to 50 mg/kg/day. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230310464A1) describes a cannabidiol (CBD) preparation for the treatment of seizures associated with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. The CBD preparation contains over 95% CBD and between 0.01 and 0.15% tetrahydrocannabinol (THC). The seizures that can be treated with this preparation include tonic, tonic-clonic, atonic, myoclonic, absence, focal seizures with impairment, and spasms.
The CBD preparation consists of at least 98% CBD and less than or equal to 2% other cannabinoids, including THC, cannabidiol-C1 (CBD-C1), cannabidivarin (CBDV), and cannabidiol-C4 (CBD-C4). The THC present is a mixture of trans-THC and cis-THC. This CBD preparation can be used in combination with other anti-epileptic drugs (AED) for enhanced effectiveness. Some examples of AED that can be used in combination with the CBD preparation are valproic acid, levetiracetam, clobazam, vigabatrin, rufinamide, topiramate, lamotrigine, and gabapentin.
The CBD used in the preparation can be isolated from cannabis plant material or prepared synthetically. The patent also specifies different dosage options for the CBD preparation. The dose of CBD can be greater than 5 mg/kg/day, 20 mg/kg/day, 25 mg/kg/day, or 50 mg/kg/day, depending on the specific needs of the patient.
In summary, this patent describes a CBD preparation for the treatment of seizures associated with HIE or anoxia at birth. The preparation contains high levels of CBD and low levels of THC, and can be used in combination with other AED. The CBD can be derived from cannabis plant material or prepared synthetically. Different dosage options are provided to accommodate varying patient needs. The patent also includes a method of administering the CBD preparation to treat seizures in patients in need.
To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
